New Drugs Approved in 2021
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Migraine and Headache
Vitamin D Supplementation Could Reduce Migraine Headache Attacks
Vitamin D supplementation had no obvious effect on attack duration or headache severity
Significant Pain Relief Observed With Intranasal Zavegepant in Migraine Trial
Zavegepant is an investigational calcitonin gene-related peptide (CGRP) receptor antagonist.
MPR Weekly Dose Podcast Episode 99
This week on the pod, there’s positive news for the COVID-19 oral antiviral candidate, Paxlovid; The CDC expands a recall for aromatherapy sprays connected to fatal cases of a rare tropical disease; The first eye drop to treat presbyopia is approved; An alternative to naloxone gets fast tracked; And a study compares the migraine treatments erenumab and topiramate.
Erenumab vs Topiramate in Patients With Migraine: Head-to-Head Study Results
The HER-MES trial included 777 adults with episodic or chronic migraine (at least 4 migraine days/month) who were treatment-naïve, not suitable for, or had previously failed up to 3 prophylactic migraine treatments.
Qulipta Approved for Preventive Treatment of Episodic Migraine
Results from ADVANCE showed statistically significantly greater decreases in mean monthly migraine days with atogepant compared with placebo.
Trudhesa Nasal Spray Now Available for Acute Treatment of Migraine
Trudhesa uses proprietary technology to deliver a lower dose (0.725mg per spray) of dihydroergotamine mesylate to the upper nasal space.
Migraine Management: How to Treat Patients With Vascular Disease
The use of triptans is contraindicated in patients with migraine and a history of ischemic stroke or coronary artery disease, although there’s no substantial evidence that they directly increase the risk for vascular events.
FDA Clears VNS Device for Paroxysmal Hemicrania, Hemicrania Continua
Patients treated with gammaCore experienced clinically meaningful benefits.
Meloxicam/Rizatriptan Combo Under Review for Migraine Treatment
The application is supported by data from the phase 3 MOMENTUM and INTERCEPT trials.
